Transcriptional dysregulation in a transgenic model of Parkinson disease

Talene A. Yacoubian, Ippolita Cantuti-Castelvetri, Bérengère Bouzou, Georgios Asteris, Pamela J McLean, Bradley T. Hyman, David G. Standaert

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Alpha-synuclein has been implicated in Parkinson disease, yet the mechanism by which alpha-synuclein causes cell injury is not understood. Using a transgenic mouse model, we evaluated the effect of alpha-synuclein overexpression on gene expression in the substantia nigra. Nigral mRNA from wild type and alpha-synuclein transgenic mice was analyzed using Affymetrix gene arrays. At 3 months, before pathological changes are apparent, we observed modest alterations in gene expression. However, nearly 200 genes were altered in expression at 9 months, when degenerative changes are more apparent. Functional genomic analysis revealed that the genes altered at 9 months were predominantly involved in gene transcription. As in human Parkinson disease, gene expression changes in the transgenic model were also modulated by gender. These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically.

Original languageEnglish (US)
Pages (from-to)515-528
Number of pages14
JournalNeurobiology of Disease
Volume29
Issue number3
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

alpha-Synuclein
Parkinson Disease
Gene Expression
Substantia Nigra
Transgenic Mice
Genes
Animal Models
Messenger RNA
Wounds and Injuries

Keywords

  • Alpha-synuclein
  • Laser capture microdissection
  • Microarray
  • Mouse
  • Parkinson disease
  • Substantia nigra
  • Transcription

ASJC Scopus subject areas

  • Neurology

Cite this

Yacoubian, T. A., Cantuti-Castelvetri, I., Bouzou, B., Asteris, G., McLean, P. J., Hyman, B. T., & Standaert, D. G. (2008). Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease, 29(3), 515-528. https://doi.org/10.1016/j.nbd.2007.11.008

Transcriptional dysregulation in a transgenic model of Parkinson disease. / Yacoubian, Talene A.; Cantuti-Castelvetri, Ippolita; Bouzou, Bérengère; Asteris, Georgios; McLean, Pamela J; Hyman, Bradley T.; Standaert, David G.

In: Neurobiology of Disease, Vol. 29, No. 3, 03.2008, p. 515-528.

Research output: Contribution to journalArticle

Yacoubian, TA, Cantuti-Castelvetri, I, Bouzou, B, Asteris, G, McLean, PJ, Hyman, BT & Standaert, DG 2008, 'Transcriptional dysregulation in a transgenic model of Parkinson disease', Neurobiology of Disease, vol. 29, no. 3, pp. 515-528. https://doi.org/10.1016/j.nbd.2007.11.008
Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, McLean PJ, Hyman BT et al. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease. 2008 Mar;29(3):515-528. https://doi.org/10.1016/j.nbd.2007.11.008
Yacoubian, Talene A. ; Cantuti-Castelvetri, Ippolita ; Bouzou, Bérengère ; Asteris, Georgios ; McLean, Pamela J ; Hyman, Bradley T. ; Standaert, David G. / Transcriptional dysregulation in a transgenic model of Parkinson disease. In: Neurobiology of Disease. 2008 ; Vol. 29, No. 3. pp. 515-528.
@article{2f6218ce4d69482ebead71b035991c80,
title = "Transcriptional dysregulation in a transgenic model of Parkinson disease",
abstract = "Alpha-synuclein has been implicated in Parkinson disease, yet the mechanism by which alpha-synuclein causes cell injury is not understood. Using a transgenic mouse model, we evaluated the effect of alpha-synuclein overexpression on gene expression in the substantia nigra. Nigral mRNA from wild type and alpha-synuclein transgenic mice was analyzed using Affymetrix gene arrays. At 3 months, before pathological changes are apparent, we observed modest alterations in gene expression. However, nearly 200 genes were altered in expression at 9 months, when degenerative changes are more apparent. Functional genomic analysis revealed that the genes altered at 9 months were predominantly involved in gene transcription. As in human Parkinson disease, gene expression changes in the transgenic model were also modulated by gender. These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically.",
keywords = "Alpha-synuclein, Laser capture microdissection, Microarray, Mouse, Parkinson disease, Substantia nigra, Transcription",
author = "Yacoubian, {Talene A.} and Ippolita Cantuti-Castelvetri and B{\'e}reng{\`e}re Bouzou and Georgios Asteris and McLean, {Pamela J} and Hyman, {Bradley T.} and Standaert, {David G.}",
year = "2008",
month = "3",
doi = "10.1016/j.nbd.2007.11.008",
language = "English (US)",
volume = "29",
pages = "515--528",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Transcriptional dysregulation in a transgenic model of Parkinson disease

AU - Yacoubian, Talene A.

AU - Cantuti-Castelvetri, Ippolita

AU - Bouzou, Bérengère

AU - Asteris, Georgios

AU - McLean, Pamela J

AU - Hyman, Bradley T.

AU - Standaert, David G.

PY - 2008/3

Y1 - 2008/3

N2 - Alpha-synuclein has been implicated in Parkinson disease, yet the mechanism by which alpha-synuclein causes cell injury is not understood. Using a transgenic mouse model, we evaluated the effect of alpha-synuclein overexpression on gene expression in the substantia nigra. Nigral mRNA from wild type and alpha-synuclein transgenic mice was analyzed using Affymetrix gene arrays. At 3 months, before pathological changes are apparent, we observed modest alterations in gene expression. However, nearly 200 genes were altered in expression at 9 months, when degenerative changes are more apparent. Functional genomic analysis revealed that the genes altered at 9 months were predominantly involved in gene transcription. As in human Parkinson disease, gene expression changes in the transgenic model were also modulated by gender. These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically.

AB - Alpha-synuclein has been implicated in Parkinson disease, yet the mechanism by which alpha-synuclein causes cell injury is not understood. Using a transgenic mouse model, we evaluated the effect of alpha-synuclein overexpression on gene expression in the substantia nigra. Nigral mRNA from wild type and alpha-synuclein transgenic mice was analyzed using Affymetrix gene arrays. At 3 months, before pathological changes are apparent, we observed modest alterations in gene expression. However, nearly 200 genes were altered in expression at 9 months, when degenerative changes are more apparent. Functional genomic analysis revealed that the genes altered at 9 months were predominantly involved in gene transcription. As in human Parkinson disease, gene expression changes in the transgenic model were also modulated by gender. These data demonstrate that alterations of gene expression are widespread in this animal model, and suggest that transcriptional dysregulation may be a disease mechanism that can be targeted therapeutically.

KW - Alpha-synuclein

KW - Laser capture microdissection

KW - Microarray

KW - Mouse

KW - Parkinson disease

KW - Substantia nigra

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=39249084455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39249084455&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2007.11.008

DO - 10.1016/j.nbd.2007.11.008

M3 - Article

C2 - 18191405

AN - SCOPUS:39249084455

VL - 29

SP - 515

EP - 528

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 3

ER -